Myelodysplastic syndrome内容预览:
(点击下图可阅读全部内容)
It is a term for a heterogeneous collection of haemopoietic stem cell disorders affecting older adults.
There is underlying ineffectiveness of haemopoiesis that results in dysplasia of bone marrow precursors and pe**heral cytopenias.
Moderate anaemia is the most common clinical problem in MDS patients, but complete myeloid bone marrow failure also occurs leading to death from bleeding or infection.
Approximately half of the patients transform to AML.
Prognosis depends on the individual’s risk factors, with median survival ranging from 5.7 years in lower-risk group to 1.2 years or less in those with higher-risk MDS.
MDS is extremely difficult to treat. Most cases are resistant to current therapies, and the most potent anti-MDS treatments (transplantation and dose intensive chemotherapy) are often too toxic for the majority of patients.
The WHO proposed changes including reclassification of RAEB-t to AML and adding a subgroup called refractory cytopenias with dysplasia (RCD)
点击下载完整版:《Myelodysplastic syndrome》
近代研究证实,乳酸林格氏液作为平衡液输入可激活PMN,使机体产生炎症反应,...[详细]
急性中毒发病急骤、病情变化迅速、发展快。群体中毒,伤害人群多。具有关部门统...[详细]